

Minnesota Medical Cannabis Pricing and Patient Experience Report

Produced and published by Sensible Change Minnesota



www.changemn.org

About Sensible Change Minnesota

Sensible Change Minnesota grew out of our sister organization, Sensible Minnesota, to allow for more flexibility to advocate for sensible drug policy reforms unburdened by its 501(c)3 lobbying restrictions.

Our team is responsible for many of the expansions of Minnesota's medical cannabis program, including:

- Intractable Pain, effective August 2016
- Post-Traumatic Stress Disorder (PTSD), effective August 2017
- Autism Spectrum Disorder, effective August 2018
- Alzheimer's Disease, effective August 2019
- Reducing the qualifications for a patient to have a caregiver in the program, effective August 2019 ([HF766, Section 6](#))
- Chronic Pain, effective August 2020
- Oral dissolvable products, effective August 2020

15,994 of Minnesota's 18,249 registered patients (87.6%) qualify for the program because of a condition that Sensible Minnesota successfully petitioned MN's Health Commissioner to add.

Sensible Change Minnesota's Board of Directors is comprised of grassroots activists, patients, caregivers, legal professionals, and union organizers. We amplify the voices of patients and consumers at the legislature.

Questions on this report can be referred to
Maren Schroeder, Policy Director, maren@changemn.org.

Key Findings

- 86 percent of surveyed registered medical cannabis patients reported price as the primary treatment barrier; 76 percent reported no access to raw cannabis plant material as a treatment barrier.
- Inhalation oil cartridges are, on average, 52 percent more expensive than raw cannabis plant material on a per mg of THC basis; capsules are 75 percent more expensive than raw cannabis plant material on a per mg of THC basis.
- 99 percent of patients surveyed by Sensible Change Minnesota support the addition of raw cannabis plant material as an allowable delivery method.

Recommendations

- Permit raw cannabis plant material as an allowable delivery method.
- Remove limitations on allowable delivery methods, or at the very least, allow Minnesota manufacturers more flexibility in product development.
- Provide for more patient care centers (dispensaries) throughout the state.
- Create marketplace competition by increasing the number of medical cannabis licenses available.
- Provide funding for pricing audits by Minnesota state regulators.

Introduction

Medical cannabis was legalized in Minnesota in 2014, and the first patients purchased products on July 1, 2015. Minnesota's program is the only established medical cannabis program in the country that does not permit any access to raw plant material. Minnesota has limited marketplace competition with only two vertically integrated manufacturers vs 715 on average (45 excluding Oklahoma with 4063) amongst other medicinal cannabis states. Initially Pennsylvania mirrored Minnesota's permitted delivery methods but modified the program by adding licensees, allowing raw cannabis, and other adjustments to adjust patient concerns regarding access and affordability.

This analysis sets forth pricing information for Minnesota, in comparison to Arizona, Florida, Illinois, New Mexico, Oklahoma, and Pennsylvania based on information that is publicly available. Oklahoma did not implement their program until 2018, so revenue numbers for 2018 are unavailable. Oklahoma is included in this paper, with limitations, in order to compare patient numbers and product pricing with a new program. Analysis within will be revised as data is made available.

Data provided within:

- Patient numbers;
- Cultivation and dispensary license numbers;
- Revenues;
- Per milligram of THC of cartridges, bulk oil, infused products, and cartridges;
- Per milligram of THC for raw cannabis products; and
- Sensible Change Minnesota patient survey results.

Additionally, Sensible Change Minnesota conducted an online survey on barriers to access for patients. The findings of that survey are found within this paper. Finally, Sensible Change Minnesota's recommendations to the legislature on accessibility are included in the conclusion.

Methodology

Data was collected using various sources (see endnotes), that were publicly available online. The author attempted to seek out consistent prices, but historical pricing of products was not found online. Patient numbers, revenues, and licenses are based on end of year numbers for 2018, except for Illinois, which provides data on a fiscal year basis, with their fiscal year ending on June 30, 2019.

Sources include state regulators' websites, statutes, rules, industry publications, and credible regional news sources. Additionally, pricing information was obtained from either dispensary websites or using the menu function on Leafly.com for the menus available via Leafly.

Patient Numbers

Minnesota had 18,127 enrolled patients, as of November 14, 2019, and has registered 30,187 patients to date; that is a loss of 40% of registered patients over four years. Data was collected on each state, the year it implemented medical cannabis, its most recent patient registry numbers, and its population. The percentage of the population that are medical cannabis patients in each state is then multiplied by Minnesota's population to achieve the "MN Patient Adjusted" number.

Table 1: Late 2019 patient numbers and adjustments

State	Implemented	As of	Patients Enrolled	Population	Patient % of Pop	MN Patient Adj
Minnesota	2015	11/14/2019	18,127 ⁱ	5,611,000	0.32%	18,157
Arizona	2010	9/1/2019	210,308 ⁱⁱ	7,171,646	2.93%	164,542
Florida	2016	11/15/2019	283,909 ⁱⁱⁱ	21,299,325	1.33%	74,792
Illinois	2013	6/30/2019	76,939 ^{iv}	12,741,080	0.60%	33,883
New Mexico	2007	9/1/2019	77,168 ^v	2,095,428	3.68%	206,635
Oklahoma	2018	11/1/2019	209,730 ^{vi}	3,943,079	5.32%	298,446
Pennsylvania	2016	11/13/2019	147,000 ^{vii}	12,807,060	1.15%	64,403

In order to compare the revenues with the patient numbers, patient numbers were compiled for 2018 End of Year reports, with the exception of Illinois, which reports based on their fiscal year ending June 30, 2019. The same methodology of using the patient population percentage was used to find the adjusted patient numbers for Minnesota.

Table 2: EOY 2018 patient numbers and adjustments

State	As of	Patients Enrolled	Population	Patient % of Pop	MN Patient Adj
Minnesota	12/31/2018	14,481 ^{viii}	5,611,000	0.26%	14,481
Arizona	12/31/2018	186,002 ^{ix}	7,171,646	2.59%	145,525
Florida [^]	1/4/2019	168,981 ^x	21,299,325	0.79%	44,516
Illinois	6/30/2019	76,939 ^{xi}	12,741,080	0.60%	33,883
New Mexico	12/31/2018	67,574 ^{xii}	2,095,428	3.22%	180,945
Oklahoma	12/31/2018	26,603 ^{xiii}	3,943,079	0.67%	37,856
Pennsylvania	10/23/2018	83,000 ^{xiv}	12,807,060	0.65%	36,364

There are far fewer patients in Minnesota when compared to other states, even those with similar programs (such as Pennsylvania and Florida). Regionally, Illinois is closer to Minnesota's numbers, but Minnesota still has fewer than 50% of the patients under the population adjusted number.

Number of Licenses and Revenue

Minnesota's two in-state manufacturers continue to lose money. Only one manufacturer, Minnesota Medical Solutions, has turned a profit since implementation. That profit was approximately \$67,000 for the 2017 year. From 2015 through 2018, Minnesota's manufacturers lost a combined \$18,743,000.

Table 3: Minnesota manufacturer net income^{xxxviii}

Year	MinnMed	Leafline
2015	-\$3,063,985	-\$2,192,989
2016	-\$1,150,843	-\$4,690,968
2017	\$67,412	-\$5,365,629
2018	-\$610,450	-\$1,818,446
Total	-\$4,757,866	-\$14,068,032

The total manufacturer losses over time is \$18,825,898. One of the biggest factors in these losses, according to Amber Shimpa, Chief Financial Officer for Vireo Health, the parent company of Minnesota Medical Solutions, is the inability to deduct business expenses for tax purposes.^{xix} At issue, is IRC 280E, which forbids deductions and credits "for any amount paid or incurred during the taxable year in carrying on any trade or business, if such trade or business consists of trafficking in controlled substances which is prohibited by Federal law or the law of any State in which such trade or business is conducted."^{xx} Minnesota adopted conforming language to U.S.C. § 280E (1982), which forbids the same deductions under state law for state tax purposes. In 2019, Minnesota passed legislation that will permit Minnesota's medical cannabis manufacturers to take the 280E deduction.

Of note, no other state in the comparison data permits 280E deductions or credits for medical cannabis businesses under their state tax codes as of September 2018.^{xxi}

Using the same audit reports, Minnesota's medical cannabis manufacturers put forth the following gross revenues.

Table 4: MN Manufacturer net sales, id.

	MinnMed	Leafline
2015	\$466,988.00	\$214,943.00
2016	\$2,217,470.00	\$1,786,313.00
2017	\$4,733,701.00	\$5,281,015.00
2018	\$7,837,934.00	\$10,102,707.00

As previously stated, Minnesota is limited to two vertically integrated manufacturers who each operate up to eight patient care centers (dispensaries). At the end of 2018, each manufacturer was authorized to operate 4 patient care centers. This is the fewest number of licenses available in any state with medical cannabis programs. To compare with the other states, the smallest number is 14 in Florida. However, in July 2019, the Florida First District Court of Appeals found the license cap unconstitutional^{xxii}, based upon the language of the constitutional amendment authorizing medical cannabis in Florida.

Table 5: License numbers for cultivators and dispensaries

State	Vertical Integration	Cultivators	Dispensaries	2018 Revenue
Minnesota	Mandatory	2	16	\$17,940,641
Arizona	Mandatory	90	116	\$400,000,000
Florida	Permissive [^]	14	88	\$250,000,000
Illinois	Permissive	22	55	\$133,000,000
New Mexico	Mandatory	35	98	\$105,800,000
Oklahoma	Permissive	1302	805	<i>Not enough data</i>
Pennsylvania	Permissive	25	60	\$132,000,000

2018 gross revenues by state:

- Minnesota: \$17,940,641^{xxiii}^{xxiv}
- Arizona: \$400,000,000^{xxv}
- Florida: \$250,000,000^{xxvi}
- Illinois: \$133,000,000^{xxvii}
- New Mexico: \$105,800,000^{xxviii}
- Oklahoma: Data is not available for 2018.
- Pennsylvania: \$132,000,000^{xxix}

Data is not publicly available to determine net income for companies in the comparison states. However, there is nothing publicly available to indicate that companies in the comparison states are operating at losses like Minnesota's two manufacturers.

Patient Spending

Patient Spending reflects that Minnesota's patients are spending less at state licensed patient care centers than patients in the other states reviewed.

Table 6: Revenue per patient

State	Current Through	Patients Enrolled	Cultivators	2018 Revenue	Rev/Pt/Yr	Rev/Pt/Mo
Minnesota	12/31/2018	14,481	2	\$17,940,641	\$1,238.91	\$103.24
Arizona	12/31/2018	186,002	90	\$400,000,000	\$2,150.51	\$179.21
Florida	1/4/2019	168,981	14	\$250,000,000	\$1,479.46	\$123.29
Illinois	6/30/2019	76,939	22	\$133,000,000	\$1,728.64	\$144.05
New Mexico	12/31/2018	67,574	35	\$105,800,000	\$1,565.69	\$130.47
Oklahoma	12/31/2018	26,603	1302	<i>Not enough data</i>		
Pennsylvania	10/23/2018	83,000	25	\$132,000,000	\$1,590.36	\$132.53

Patient access barriers are discussed below, but data from the Minnesota Department of Health indicates that 51%^{xxx} of Minnesota's registered patients were receiving a reduced annual registration fee based on their receipt of Minnesota Care, Social Security Disability, Supplemental Security Income, Medicaid/Medical Assistance, or CHAMPVA at the end of 2018.

Medical Cannabis Pricing

As of the publication of this paper, no comprehensive price comparison has been published to the author's knowledge.

Minnesota restricts the delivery methods for medical cannabis, and explicitly forbids the use of raw cannabis material. For the purpose of comparing Minnesota's price per milligram of THC with other, less restrictive, states, vaporizer cartridges, bulk oils, infused liquids, and capsules are looked at. Prices were obtained using dispensary menus available publicly online, and the details of the prices pulled are attached hereto as Appendix A.

For cartridges, Minnesota only has three options for high-THC products - MinnMed Red Distillate, MinnMed Red, and Leafline Tangerine, so those prices were used to form an average that is compared against the average price based on four products of similar quality from the comparison states. For bulk oils, infused liquids, and capsules, one high-THC product from each manufacturer is averaged against two products of similar composition from the comparison states. Of note, the cartridges and bulk oil are used for vaporizing, and are the patients' alternative to smokable or vaporizable raw cannabis.

Table 7: Price per milligram of THC

	Cartridges	Bulk Oil	Infused	Capsules	Avg \$/mg
Minnesota	\$0.18	\$0.17	\$0.18	\$0.26	\$0.20
Arizona	\$0.07	\$0.04	\$0.17	\$0.12	\$0.10
Florida	\$0.14	\$0.10	\$0.13	\$0.22	\$0.15
Illinois	\$0.13	\$0.09	\$0.27	\$0.27	\$0.19
New Mexico	\$0.08	\$0.07	\$0.08	\$0.18	\$0.10
Oklahoma	\$0.08	\$0.06	\$0.23	\$0.27	\$0.16
Pennsylvania	\$0.15	\$0.11	\$0.16	\$0.28	\$0.17

Based on this comparison, Minnesota's patients pay a premium, in comparison to the other states, for vaporizable products -- with Minnesota having the highest price per milligram for these products. This is especially concerning, as over 50% of the products purchased are for inhalation.^{xxxi}

Patient Value

Minnesota has the highest average price per milligram of THC when it comes to inhalable products. Based on the per month revenue, and the price per milligram, below is a comparison of how many milligrams of THC a patient can expect to receive on average under Minnesota's prices (actual numbers) compared to the number of milligrams a patient would receive spending the same amount in a comparison state.

Table 8: Milligrams per month based on patient spending

	Avg \$/mg	Avg. Spent/mo (2018)	mg/mo	mg/mo/patient @ \$103
Minnesota	\$0.20	\$103.24	522	522
Arizona	\$0.10	\$179.21	1757	1012
Florida	\$0.15	\$123.29	850	712
Illinois	\$0.19	\$144.05	764	548
New Mexico	\$0.10	\$130.47	1303	1031
Oklahoma	\$0.16	<i>Not enough data</i>		
Pennsylvania	\$0.17	\$132.53	761	593

The above table indicates that a patient in New Mexico would receive 1,031 mgs of THC for the same amount they pay for 522 mgs of THC in Minnesota, when averaged against the products allowed in Minnesota. The patient would receive nearly two-times the medical cannabinoid in New Mexico than they receive in Minnesota.

Raw Cannabis

Minnesota is one of the only states with a comprehensive medical cannabis program (one that does not have a THC limit on products and provides for regulated sales to patients) that does not allow for raw cannabis material. The price per milligram of THC from raw cannabis plant material is significantly lower than the price per milligram of THC for other medical cannabis products.

Similar methodology was used to determine the price per milligram for raw cannabis plant material. Four products in Arizona, Illinois, New Mexico, Oklahoma, and Pennsylvania, and three products in Florida, were chosen and the price per milligram of THC averaged. The dollar amount spent by patients each month is then listed next to the number of milligrams purchased for that dollar amount.

Table 9: Price per milligram and milligram per patient comparison w/plant material

	\$/mg plant	Pt/mo	Mg/mo
Minnesota	N/A	\$103	N/A
Arizona	\$0.04	\$179	4,480
Florida	\$0.07	\$123	1,761
Illinois	\$0.06	\$144	2,401
New Mexico	\$0.05	\$130	2,609
Oklahoma	\$0.05	<i>Not enough data</i>	
Pennsylvania	\$0.07	\$133	1,893

The next data set compares how many milligrams of THC from raw cannabis plant material a patient can purchase for \$103, the average revenue per patient in Minnesota, in the comparison states.

Table 10: milligrams per month based on MN patient spending

	\$/mg plant	Mg/Mo for \$103
Minnesota	N/A	N/A
Arizona	\$0.04	2581
Florida	\$0.07	1475
Illinois	\$0.06	1721
New Mexico	\$0.05	2065
Oklahoma	\$0.05	2065
Pennsylvania	\$0.07	1475

A Minnesota patient spending \$103 per month, currently receives on average, 522 milligrams of THC from oil, pill, or liquid products. Spending that same \$103 on raw cannabis plant material in a comparison state, a patient could afford up to nearly five-times more milligrams of THC for their dollar.

Patient Feedback

From July 10, 2019 through October 1, 2019, Sensible Change Minnesota used social media to solicit feedback from patients on Minnesota's medical cannabis program based on observations we have from four years of working directly with patients.

In total, 118 responses were received. Eighty-two (82) indicated they are currently a patient, indicated they were once registered but allowed their registration to lapse, use medicinally but have not registered for the program, and twelve (12) indicated they are not a patient. For the purpose of data analysis, "Patient" means that they are currently a patient, use medicinally but are not registered for the program, or were a patient but allowed their registration to lapse -- a total of 106 respondents.

Table 11: Are you a registered medical cannabis patient?

Yes	82
No	12
I use cannabis medicinally, but never registered for the program	16
I was, but allowed my registration to lapse	8

Sensible Change Minnesota identified five different barriers to access: price, access to raw cannabis, dispensary locations, not enough producers, and lack of product diversity. Patients overwhelmingly chose price (90%) and no access to raw cannabis (76%) as the top two barriers to access, followed by lack of product diversity (55%), dispensary locations (45%), and not enough producers (40%).

Table 12: Barriers to access by patient-type

	Yes	Not Registered	Lapsed	All "Patients"
Price	86.6%	81.3%	62.5%	84.0%
No access to raw cannabis	72.0%	62.5%	87.5%	71.7%
Dispensary locations	39.0%	31.3%	25.0%	36.8%
Not enough producers	42.7%	18.8%	25.0%	37.7%
Lack of product diversity	58.5%	75.0%	37.5%	53.8%

Additionally, given that Minnesota is the only state with an established medical cannabis program that does not allow raw cannabis, Sensible Change Minnesota asked respondents if they support the addition of raw cannabis in the medical cannabis program. 99% of respondents answered “yes,” including 100% of those not registered and those that are lapsed.

Table 13: Supports the addition of raw cannabis

Yes	Not Registered	Lapsed	All "Patients"	All Respondents
98.8%	100.0%	100.0%	99.06%	98.31%

Patients answering the survey were from all corners of the state. Broken down by congressional districts, the patient demographics are relatively well disbursed, with a smaller than desired response from northern Minnesota.

Table 14: Respondents by U.S. Congressional District

Respondents by US Congressional District	
Congressional District 1	16.67%
Congressional District 2	16.67%
Congressional District 3	12.28%
Congressional District 4	11.40%
Congressional District 5	14.91%
Congressional District 6	16.67%
Congressional District 7	5.26%
Congressional District 8	6.14%

Conclusion and Recommendations

The values presented in this report indicate significant patient access barriers, especially cost, with Minnesota’s medical cannabis program. Minnesota must take steps to increase patient access to medical cannabis through the addition of raw cannabis plant material as a delivery method, diversification of available products, and increasing competition in the marketplace. With these changes, Minnesota’s patient numbers will increase, which will result in increased revenues for Minnesota’s medical cannabis manufacturers and improved access for its patients.

Pricing Comparison Data

Data collected 10/2019-11/2019; last updated 11/8/2019 for Minnesota

Cartridge Prices

State	Producer	Dispensary	Product	THC Content (mg)	Product Price	Price per mg
Minnesota	MinnMed	MinnMed	Red Prefilled Vaporizer 0.5 mL	250	\$50.00	\$0.20
Minnesota	MinnMed	MinnMed	Red prefilled vaporizer - distillate 0.5mL	380	\$65.00	\$0.17
Minnesota	Leafline	Leafline	Tangerine Vaporization Cartridge 0.5 mL	400	\$72.54	\$0.18
Arizona	Item9 Labs	The Good Dispensary	Pink Champagne (I) 500 mg	470	\$40.00	\$0.09
Arizona	MPX Melting Point Extracts	The Holistic Center	500 mg Indica: Northern Lights	439	\$32.00	\$0.07
Arizona	Select Oil	MedMen	Orange Dreamsicle	890	\$60.00	\$0.07
Arizona	DRIP Oils + Extracts	Green Pharms	DRIP Clear C-Cell Gelato 33	846	\$60.00	\$0.07
Florida	GrowHealthy	GrowHealthy	MIND Boss (Sativa)	409	\$50.00	\$0.12
Florida	Curaleaf	Curaleaf	THC Vape Cartridge Pineapple Express	425	\$51.00	\$0.12
Florida	Evolab	Harvest	Strawberry Lemonade Chroma Colors Evolab	205	\$29.00	\$0.14
Florida	G Pen (Grenco Science)	MUV	MUV G Pen Gio - Clementine	350	\$60.00	\$0.17
Illinois	Rythm	Mission Dispensaries	Citrus Zest 0.5 mg Cartridge	367.3	\$55.00	\$0.15
Illinois	GTI	Columbia Care Illinois	Durban CO2 500mg GTI	430.3	\$50.00	\$0.12
Illinois	Ataraxia	Columbia Care Illinois	Mater Kush 500mg	416.5	\$70.00	\$0.17
Illinois	Progressive Treatment Solutions	The Dispensary Fulton	Cartridge - Banana Kush	705	\$58.00	\$0.08
New Mexico	UH Cartridges	Ultra Health Albuquerque	UH Cartridges	340	\$35.00	\$0.10
New Mexico	Vitality Extracts	Urban Wellness	Elevated - So Cal Master Kush	690	\$23.00	\$0.03
New Mexico	Phyto	CG Corrigan	Phyto - 412 mg Distillate PatPen Vape Cartridge	412	\$40.00	\$0.10
New Mexico	Bhang	Shift Jefferson	Refined Oil Cartridge	417.5	\$40.00	\$0.10
Oklahoma	Red Bud Elixers	Project Releaf	Red Bud Skunk #1 Weekender	368	\$35.00	\$0.10
Oklahoma	Red Sky	Atomic Bud LLC	RS Clementine Cart	418.5	\$50.00	\$0.12
Oklahoma	Xen Xtracts	Green Leaf Cannabis	Purple Punch 1g Cart	873	\$60.00	\$0.07
Oklahoma	Oklahoma Dab Lab	Fire Leaf Dispensary	Trainwreck 0.5 G Cartridge	455.5	\$25.00	\$0.05
Pennsylvania	Prime Wellness	Maitri Medicinals	JR Cash 500 mg Cart	217	\$40.00	\$0.18
Pennsylvania	Vireo	Herbology	Red Jack Herer Distillate .5g	343	\$50.00	\$0.15
Pennsylvania	Grassroots	Herbology	Grassroots (CO2) Indica Blend	789	\$90.00	\$0.11
Pennsylvania	Liberty	Mission Allentown	Liberty Apple Jacks 500 mg Distillate Cartridge	349.5	\$60.00	\$0.17

Bulk Oil Prices

State	Producer	Dispensary	Product Description	THC (mg)	Product Cost	\$/mg
Minnesota	MinnMed	MinnMed	Red Distillate Bulk Oil for Vaporization - 1 gram Syringe	760	\$125.00	\$0.16
Minnesota	Leafline	Leafline	Tangerine Bulk Oil 1 mL Syringe	800	\$145.08	\$0.18
Arizona	Venom Extracts	MedMen	Golden Strawberry Shatter	721	\$20.00	\$0.03
Arizona	PuraEarth	The Good Dispensary	RAW THC Oil Syringe 1000mg	1000	\$55.00	\$0.06
Florida	MUV Prodcuts	MUV	MUV Cannabis Distillate	405	\$45.00	\$0.11
Florida	Surterra Wellness	Surterra Wellness	Relief Pure Reserve Oil	810	\$65.00	\$0.08
Illinois	Revolution	Mission Dispensaries	Purple Dream Drizzler 1G Syringe	784.6	\$90.00	\$0.11
Illinois	Shelby County Community Services	The Dispensary Fulton	9lb Hammer CO2 Oil	697	\$42.00	\$0.06
New Mexico	Phyto	CG Albuquerque	Synergy 689 mg FSO Sativa Syringe	677	\$30.00	\$0.04
New Mexico	Budder Pros	Urban Wellness	Pure Syringe - Green Ghost	779	\$70.00	\$0.09
Oklahoma	Oklahoma Pure	Fire Leaf Dispensary	Strawberry Fields Syringe 1G	952	\$50.00	\$0.05
Oklahoma	1937	Medicinal Marijuana	1g Durban Poison Distillate	850	\$60.00	\$0.07
Pennsylvania	Vireo	Herbology	Red Jack Herer Distillate 1g	686	\$90.00	\$0.13
Pennsylvania	Grassroots	Nature's Medicine	Full Spectrum RSO	827	\$75.00	\$0.09

Infused Liquids

State	Producer	Dispensary	Product Description	THC (mg)	Product Cost	\$/mg
Minnesota	MinnMed	MinnMed	Red Oral Solution 25 mL Bottle	625	\$105.00	\$0.17
Minnesota	Leafline	Leafline	Tangerine Oral Suspension, 120 mL	240	\$45.78	\$0.19
Arizona	Green Halo Edibles	The Hoslistic Center	Chronic Health Cycerine Tincture	200	\$35.00	\$0.18
Arizona	Keef Brands	MedMen	Purple Passion Soda	100	\$17.00	\$0.17
Florida	Curaleaf	Curaleaf	THC Tincture D8:D9 Lemon	1200	\$140.00	\$0.12
Florida	MUV	MUV	Sublingual Tincture	300	\$40.00	\$0.13
Illinois	Zoots	Verilife	ZootDrops Lemon Relaxation Blend	100	\$30.00	\$0.30
Illinois	PTS Tonic	FloraMedEx	Pomegranate Acai 100 mg 12oz	100	\$24.45	\$0.24
New Mexico	Panaxia	Ultra Health	Medical Cannabis Tincture Oil	1600	\$70.00	\$0.04
New Mexico	Bud Nectar	PurLife	Hybrid Tincture	300	\$32.48	\$0.11
Oklahoma	US Cannabis Pharma	Medicinal Marijuana	Tincture 600mg	600	\$70.00	\$0.12
Oklahoma	Lotus Gold	Lotus Gold	Level 2 THC Tropical 30mL	203	\$70.00	\$0.34
Pennsylvania	Ilera	Nature's Medicine	THC+ Tincture	300	\$50.00	\$0.17
Pennsylvania	Prime	Herbology	Prime THC Blend	480	\$70.00	\$0.15

Capsules

State	Producer	Dispensary	Product Description	THC (mg)	Product Cost	\$/mg
Minnesota	MinnMed	MinnMed	Red Capsules, 30 count, 2.5 mg	75	\$24.00	\$0.32
Minnesota	Leafline	Leafline	Tangerine Capsule, 30 count, 5 mg	150	\$28.61	\$0.19
Arizona	KIND Concentrates	MedMen	THC Capsules	200	\$28.00	\$0.14
Arizona	Uncle Herbs Health Center	Health for Life	Uncle Herbs Chill Pill - Night	800	\$80.00	\$0.10
Florida	Surterra Wellness	Surterra Wellness	Relief Theragels 9:1	720	\$150.00	\$0.21
Florida	Curaleaf	Curaleaf	THC Tablet - Hybrid 5 mg	150	\$35.00	\$0.23
Illinois	Cresco Labs	Urbana	THC Indica Capsules	100	\$25.00	\$0.25
Illinois	Progresive Treatment Solutions	Maribis of Springfield	PTS Capsules Chill Pills	100	\$28.00	\$0.28
New Mexico	Panaxia	Ultra Health	10mg THC Oral Tablets	100	\$25.00	\$0.25
New Mexico	Pecos Valley Production	Pecos Valley Production	THC Canna Capsules	400	\$40.00	\$0.10
Oklahoma	Creekside	Emerald Elite THC	Creekside Capsules 10 CT	50	\$17.34	\$0.35
Oklahoma	Woke Wellness	Woke Wellness	Rosin Sugar Capsules	500	\$100.00	\$0.20
Pennsylvania	Cresco	Nature's Medicine	Awake Capsules	100	\$35.00	\$0.35
Pennsylvania	Terrapin	Nature's Medicine	Ivent Capsules	50	\$10.00	\$0.20

Raw Cannabis Plant Material

State	Producer	Dispensary	Product	THC %	THC mg	Product Price	Price per mg
Arizona	High Grade AZ	The Holistic Center	Blueberry Shortcake #12 (indica) 3.5 g	24.60%	861	\$35.00	\$0.04
Arizona	Harvest of Tucson	Health for Life	Oz: Bruce Banner (hybrid) 28 g	24.60%	6888	\$125.00	\$0.02
Arizona	Nature's Medicines	Nature's Medicines	Sensi Star 1g	20.50%	205	\$6.00	\$0.03
Arizona	Sky Cannabis	Sky Dispensaries	Slap Wagon 1 g	19.47%	194.7	\$17.00	\$0.09
Florida	GrowHealthy	GrowHealthy	BALANCE Grape Stomper (Hybrid) 3.5g	18.40%	644	\$50.00	\$0.08
Florida	3 Boys Farm	One Plant	Cathy's Choice 3.5g	18.90%	661.5	\$48.00	\$0.07
Florida	Trulieve	Trulieve	Smokable TruFlower - indica 3.5g	20.00%	700	\$35.00	\$0.05
Illinois	Goldleaf	Nature's Treatment	G6 3.5g	29.10%	1018.5	\$65.00	\$0.06
Illinois	Bedford Grow	Maribis of Springfield	BG Money's Pug Life 3.5g	22.21%	777.35	\$55.00	\$0.07
Illinois	Cresco by Cresco Labs	Phoenix Botanical	Animal Cookies 3.5g	28.84%	1009.54	\$55.00	\$0.05
Illinois	Matter	Verilife	Mandarin Cookies 3.5 g	24.58%	860.3	\$50.00	\$0.06
New Mexico	Unknown	The Verdes Foundation	Blue Dream 1g	25.00%	250	\$10.50	\$0.04
New Mexico	Southwest Wellness	Ultra Health	Blueberry Haze 1 g	21.30%	213	\$14.00	\$0.07
New Mexico	Harvest	Urban Wellness	Cherry Dosi 1g	26.13%	261.3	\$11.00	\$0.04
New Mexico	Unknown	Red Barn Growers	Sinmint Cookies	26.61%	266.1	\$14.00	\$0.05
Oklahoma	Unknown	Project Releaf	Original Glue 1 g	22.00%	220	\$10.00	\$0.05
Oklahoma	Lotus Gold	Lotus Gold	Lotus Gold Cannabis Flower Jack Monkey	21.80%	763	\$39.99	\$0.05
Oklahoma	Black Jack	Atomic Bud LLC	Black Jack 1g	19.80%	198	\$10.00	\$0.05
Oklahoma	Unknown	Green Leaf Cannabis	SFV OG 1g	23.00%	230	\$15.00	\$0.07
Pennsylvania	Rythm	Rise Cannabis	PA Dutch 3.5 g	24.40%	854	\$55.00	\$0.06
Pennsylvania	Terrapin	Rise Cannabis	Moonshine Haze 3.5g	14.80%	518	\$45.00	\$0.09
Pennsylvania	Grassroots	Herbology	TRE OG 1g	26.60%	266	\$20.00	\$0.08
Pennsylvania	Terrapin	Organic Remedies	Cherry Diesel Dry Leaf 3.5g	22.00%	770	\$42.00	\$0.05

References

- ⁱ Minnesota Office of Medical Cannabis; Medical Cannabis Weekly Updates of Registration Counts November 14, 2019; <https://www.health.state.mn.us/people/cannabis/about/medicalcannabisstats.html> accessed November 17, 2019
- ⁱⁱ Arizona Department of Health Services Licensing Division; Arizona Medical Marijuana Program September 2019 Monthly Report; <https://www.azdhs.gov/documents/licensing/medical-marijuana/reports/2019/2019-sep-monthly-report.pdf> accessed November 17, 2019
- ⁱⁱⁱ Florida Health, Office of Medical Marijuana Use; November 15, 2019 weekly update; https://s27415.pcdn.co/wp-content/uploads/ommu_updates/2019/111519-OMMU-Update.pdf accessed November 17, 2019
- ^{iv} Illinois Department of Public Health; Annual Progress Report 2019; <http://www.dph.illinois.gov/sites/default/files/publications/2019-mcipp-annual-report.pdf> accessed November 17, 2019
- ^v New Mexico Department of Health; Medical Cannabis Program Patient Statics September 2019; <https://nmhealth.org/publication/view/report/5341/> accessed November 17, 2019
- ^{vi} Oklahoma Medical Marijuana Authority; Tweet dated November 1, 2019; <https://twitter.com/OMMAOK/status/1190373028242296834> accessed November 17, 2019
- ^{vii} PA Department of Health; Tweet dated November 13, 2019; <https://twitter.com/PAHealthDept/status/1194647000970596353> accessed November 17, 2019
- ^{viii} Minnesota Department of Health; Medical Cannabis Program Update January 2019; <https://www.health.state.mn.us/people/cannabis/docs/about/update0119.pdf> accessed November 17, 2019
- ^{ix} Arizona Department of Health Services Licensing Division; Arizona Medical Marijuana Program December 2018 Monthly Report; <https://www.azdhs.gov/documents/licensing/medical-marijuana/reports/2018/2018-dec-monthly-report.pdf> accessed November 17, 2019
- ^x Florida Health, Office of Medical Marijuana Use; January 4, 2019 weekly update; https://s27415.pcdn.co/wp-content/uploads/ommu_updates/2019/010419-OMMU-Update.pdf accessed November 17, 2019
- ^{xi} Illinois Department of Public Health; Annual Progress Report 2019; <http://www.dph.illinois.gov/sites/default/files/publications/2019-mcipp-annual-report.pdf> accessed November 17, 2019
- ^{xii} Ultra Health; N.M. Medical Cannabis Program Finishes 2018 with \$106 Million in Sales; <https://www.globenewswire.com/news-release/2019/01/25/1705705/0/en/N-M-Medical-Cannabis-Program-Finishes-2018-With-106-Million-in-Sales.html> accessed November 17, 2019
- ^{xiii} Oklahoma Medical Marijuana Authority; Tweet dated December 31, 2019; <https://twitter.com/OMMAOK/status/1079768890543095808> accessed November 17, 2019
- ^{xiv} Marijuana Policy Project; Medical Marijuana Patient Numbers; <https://www.mpp.org/issues/medical-marijuana/state-by-state-medical-marijuana-laws/medical-marijuana-patient-numbers/> accessed November 17, 2019
- ^{xv} Bridge West LLC; Minnesota Medical Solutions, LLC and Variable Interest Entity Consolidated Financial Statements for the Years Ended December 31, 2016 and 2015
- ^{xvi} Smith Schafer & Associates, Ltd.; Leafline Labs, LLC Financial Statements December 31, 2016 and 2015
- ^{xvii} Bridge West LLC; Minnesota Medical Solutions, LLC Financial Statements for the Years Ended December 31, 2018 and 2017
- ^{xviii} Smith Schafer & Associates, Ltd.; Leafline Labs, LLC Financial Statements December 31, 2017 and 2018
- ^{xix} Hubbard, R. Why do medical cannabis companies pay the highest corporate taxes in Minnesota?, Faribault Daily News; https://www.southernminn.com/faribault_daily_news/news/state/article_337d2ded-2893-533f-8110-a0b980644ef1.html accessed November 22, 2019

^{xx} 26 U.S.C. § 280E (1982)

^{xxi} Benda J., Mills, J. Cannabis Industry State Tax Guide, September 2018;
<https://www.foxrothschild.com/content/uploads/2018/08/Cannabis-Tax-E-book-Septemberv2-2018-2.pdf>
accessed November 22, 2019

^{xxii} Fla. Dep't of Health v. Florigrown, LLC (Fla. App., 2019)

^{xxiii} Bridge West LLC; Minnesota Medical Solutions, LLC Financial Statements for the Years Ended December 31, 2018 and 2017

^{xxiv} Smith Schafer & Associates, Ltd.; Leafline Labs, LLC Financial Statements December 31, 2017 and 2018

^{xxv} Marijuana Business Daily; Arizona medical marijuana sales increased 41% in 2018; January 18, 2019;
<https://mjbizdaily.com/arizona-medical-marijuana-sales-increased-41-percent-in-2018/> accessed November 17, 2019

^{xxvi} Marijuana Business Daily; How Florida's \$250M medical cannabis market could open up to new businesses in 2019; December 18, 2018; <https://mjbizdaily.com/florida-medical-cannabis-2019/> accessed November 17, 2019

^{xxvii} Marijuana Business Daily; Chart: Illinois medical marijuana sales strong ahead of opioid-alternative program; January 21, 2019; <https://mjbizdaily.com/illinois-medical-marijuana-sales-opioid-alternative-program/> accessed November 17, 2019

^{xxviii} Ultra Health; N.M. medical cannabis program finishes 2018 with \$106 million in sales; January 25, 2019;
<https://www.globenewswire.com/news-release/2019/01/25/1705705/0/en/N-M-Medical-Cannabis-Program-Finishes-2018-With-106-Million-in-Sales.html> accessed November 17, 2019

^{xxix} Marijuana Business Daily; Medical marijuana sales in Pennsylvania exceed \$132M in first year; February 18, 2019; <https://mjbizdaily.com/pennsylvania-medical-cannabis-sales-exceed-132-million-first-year/> accessed November 17, 2019

^{xxx} Minnesota Department of Health; Medical Cannabis Program Update January 2019;
<https://www.health.state.mn.us/people/cannabis/docs/about/update0119.pdf> accessed November 17, 2019

^{xxxi} Minnesota Department of Health; Medical Cannabis Use Patterns: Patients with First Enrollment July 2015-June 2017; October 11, 2019;
https://www.health.state.mn.us/people/cannabis/docs/about/cohort/c2015_2017_mcusepttns.pdf accessed November 17, 2019.